Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single center retrospective study of daratumumab, pomalidomide, and dexamethasone (DPd) alone versus (vs) DPd followed by ASCT in patients with relapsed/refractory multiple myeloma

Next Previous
Trial Profile

Single center retrospective study of daratumumab, pomalidomide, and dexamethasone (DPd) alone versus (vs) DPd followed by ASCT in patients with relapsed/refractory multiple myeloma

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daratumumab (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Pomalidomide (Primary) ; Melphalan
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 13 Jan 2023 New trial record
  • 13 Dec 2022 Results(n=97) assessing Hematological and Non-Hematological Toxicities in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide, and Dexamethasone (DPd) presented at the 64th American Society of Hematology Annual Meeting and Exposition
  • 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top